Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis

Nature Reviews Nephrology

Volumn 8, Issue 8, 2012, Pages 476-483

  Chen, Min ^a   Gao, Ying ^a   Guo, Xiao Hui ^a   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; ANTITHYROID AGENT; BENZYLTHIOURACIL; BETA2 GLYCOPROTEIN 1; CARBIMAZOLE; CEFOTAXIME; CLOZAPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEVAMISOLE; METHYLPREDNISOLONE; MINOCYCLINE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE; PHENYTOIN; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; THIAMAZOLE; THIORIDAZINE; THIOUREA;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM EXPOSURE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; AUTOIMMUNE DISEASES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS; PROGNOSIS; PROPYLTHIOURACIL; RISK FACTORS; VASCULITIS;

EID: 84864362580     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.108     Document Type: Review

References (93)

1. Jennette, J. C. & Falk, R. J. Small-vessel vasculitis. N. Engl. J. Med. 337, 1512-1523 (1997). (Pubitemid 27495778)
2. Hagen, E. C. et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 53, 743-753 (1998). (Pubitemid 28124291)
3. Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115-4119 (1990). (Pubitemid 20217992)
4. Charles, L. A., Caldas, M. L., Falk, R. J., Terrell, R. S. & Jennette, J. C. Antibodies against granule proteins activate neutrophils in vitro. J. Leukoc. Biol. 50, 539-546 (1991).
5. Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955-963 (2002).
6. Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355-3364 (2006). (Pubitemid 44865278)
7. Little, MA. et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106, 2050-2058 (2005). (Pubitemid 41291719)
8. Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180-2188 (2007). (Pubitemid 47041083)
9. De Lind Van Wijngaarden, R. A. et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 18, 2189-2197 (2007).
10. Birck, R., Schmitt, W. H., Kaelsch, I. A. & Van Der Woude, F. J. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: Systematic review. Am. J. Kidney Dis. 47, 15-23 (2006). (Pubitemid 41828262)
11. Finkielman, J. D. et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 147, 611-619 (2007). (Pubitemid 351664480)
12. Chen, M. & Kallenberg, C. G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun. Rev. 9, A293-A298 (2010).
13. Chen, M. & Kallenberg, C. G. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat. Rev. Rheumatol. 6, 653-664 (2010).
14. Wiik, A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res. Ther. 7, 191-192 (2005). (Pubitemid 41335154)
15. Aloush, V., Litinsky, I., Caspi, D. & Elkayam, O. Propylthiouracil-induced autoimmune syndromes: Two distinct clinical presentations with different course and management. Semin. Arthritis Rheum. 36, 4-9 (2006). (Pubitemid 44144499)
16. Pillinger, M. H. & Staud, R. Propylthiouracil and antineutrophil cytoplasmic antibody associated vasculitis: The detective finds a clue. Semin. Arthritis Rheum. 36, 1-3 (2006). (Pubitemid 44128598)
17. Bonaci-Nikolic, B., Nikolic, M. M., Andrejevic, S., Zoric, S. & Bukilica, M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: Comparison with idiopathic ANCA vasculitides. Arthritis Res. Ther. 7, R1072-R1081 (2005).
18. Wiik, A. Drug-induced vasculitis. Curr. Opin. Rheumatol. 20, 35-39 (2008). (Pubitemid 351339430)
19. Dolman, K. M. et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342, 651-652 (1993). (Pubitemid 23271506)
20. Gao, Y. et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr. Res. 30, 205-213 (2004). (Pubitemid 39243121)
21. Zhao, M. H., Chen, M., Gao, Y. & Wang, H. Y. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 69, 1477-1481 (2006).
22. Hori, Y. et al. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. Nephron 74, 734-735 (1996). (Pubitemid 26396195)
23. Kawachi, Y., Nukaga, H., Hoshino, M., Iwata, M. & Otsuka, F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin. Exp. Dermatol. 20, 345-347 (1995).
24. Nässberger, L., Johansson, A. C., Björck, S. & Sjöholm, A. G. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: Autoimmune responses in glomerulonephritis due to hydralazine treatment. J. Intern. Med. 229, 261-265 (1991).
25. Almroth, G., Eneström, S., Hed, J., Samuelsson, I. & Sjöström, P. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J. Intern. Med. 231, 37-42 (1992).
26. Stokes, M. B. et al. Development of glomerulonephritis during anti TNF α therapy for rheumatoid arthritis. Nephrol. Dial. Transplant. 20, 1400-1406 (2005). (Pubitemid 41430613)
27. De Bandt, M. & Saint-Marcoux, B. Tumour necrosis factor α blockade and the risk of vasculitis. Ann. Rheum. Dis. 65, 1534-1535 (2006). (Pubitemid 44629140)
28. Simms, R., Kipgen, D., Dahill, S., Marshall, D. & Rodger, R. S. ANCA-associated renal vasculitis following anti-tumor necrosis factor α therapy. Am. J. Kidney Dis. 51, e11-e14 (2008). (Pubitemid 351273474)
29. Salerno, S. M. et al. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegeners granulomatosis. Chest 110, 556-559 (1996). (Pubitemid 26269293)
30. Denissen, N. H., Peters, J. G., Masereeuw, R. & Barrera, P. Can sulfasalazine therapy induce or exacerbate Wegeners granulomatosis? Scand. J. Rheumatol. 37, 72-74 (2008).
31. Bienaimé, F. et al. D Penicillamine induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am. J. Kidney Dis. 50, 821-825 (2007). (Pubitemid 47588548)
32. Locke, I. C., Worrall, J. G., Leaker, B., Black, C. M. & Cambridge, G. Autoantibodies to myeloperoxidase in systemic sclerosis. J. Rheumatol. 24, 86-89 (1997). (Pubitemid 27059863)
33. Sethi, S., Sahani, M. & Oei, L. S. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am. J. Kidney Dis. 42, E27-E31 (2003).
34. Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005). (Pubitemid 40300299)
35. Gao, Y. & Zhao, M. H. Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 14, 33-41 (2009).
36. Kimura, S. & Ikeda-Saito, M. Human myeloperoxidase and thyroid peroxidase, two enzymes with separate and distinct physiological functions, are evolutionarily related members of the same gene family. Proteins 3, 113-120 (1988).
37. Nakamura, H. et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves disease. J. Clin. Endocrinol. Metab. 92, 2157-2162 (2007). (Pubitemid 46997115)
38. Bilu Martin, D., Deng, A., Gaspari, A. & Pearson, F. Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in a patient with Graves disease treated with methimazole. Skinmed 5, 302-305 (2006).
39. Tsai, M. H., Chang, Y. L., Wu, V. C., Chang, C. C. & Huang, T. S. Methimazole-induced pulmonary hemorrhage associated with antimyeloperoxidase- antineutrophil cytoplasmic antibody: A case report. J. Formos. Med. Assoc. 100, 772-775 (2001).
40. DCruz, D. et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br. J. Rheumatol. 34, 1090-1091 (1995).
41. Calañas-Continente, A. et al. Necrotizing glomerulonephritis and pulmonary hemorrhage associated with carbimazole therapy. Thyroid 15, 286-288 (2005). (Pubitemid 40418696)
42. Gumà, M. et al. Frequency of antineutrophil cytoplasmic antibody in Graves disease patients treated with methimazole. J. Clin. Endocrinol. Metab. 88, 2141-2146 (2003). (Pubitemid 36549890)
43. Wada, N. et al. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil and thiamazole. Endocr. J. 49, 329-334 (2002). (Pubitemid 34832305)
44. Huang, C. N., Hsu, T. C., Chou, H. H. & Tsay, G. J. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves disease treated with propylthiouracil or methimazole in Taiwan. J. Formos. Med. Assoc. 103, 274-279 (2004). (Pubitemid 39069690)
45. Slot, M. C., Links, T. P., Stegeman, C. A. & Tervaert, J. W. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum. 53, 108-113 (2005). (Pubitemid 40216359)
46. Stankus, S. J. & Johnson, N. T. Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest 102, 1595-1596 (1992).
47. Yazisiz, V., Ongüt, G., Terzioglu, E. & Karayalçin, U. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int. J. Clin. Pract. 64, 19-24 (2010).
48. Fujieda, M., Hattori, M., Kurayama, H. & Koitabashi, Y. Members and Coworkers of the Japanese Society for Pediatric Nephrology. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. J. Am. Soc. Nephrol. 13, 437-445 (2002). (Pubitemid 34106286)
49. Sera, N. et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves disease. Thyroid 10, 595-599 (2000). (Pubitemid 30670620)
50. Harper, L. et al. Propylthiouracil and carbimazole associated- antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves disease. Clin. Endocrinol. (Oxf.) 60, 671-675 (2004). (Pubitemid 38788072)
51. Noh, J. Y. et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J. Clin. Endocrinol. Metab. 94, 2806-2811 (2009).
52. Cin, M. O. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves patients treated with propylthiouracil. Int. J. Clin. Pract. 63, 299-302 (2009).
53. Lee, E. et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem. Pharmacol. 37, 2151-2153 (1988).
54. Lee, E., Miki, Y., Hosokawa, M., Sayo, H. & Kariya, K. Oxidative metabolism of propylthiouracil by peroxidases from rat bone marrow. Xenobiotica 18, 1135-1142 (1988). (Pubitemid 18267202)
55. Zhang, A. H., Chen, M., Gao, Y., Zhao, M. H. & Wang, H. Y. Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin. Immunol. 122, 187-193 (2007). (Pubitemid 46073894)
56. Jiang, X., Khursigara, G. & Rubin, R. L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266, 810-813 (1994). (Pubitemid 24359291)
57. von Schmiedeberg, S., Goebel, C., Gleichmann, E. & Uetrecht, J. Neutrophils and drug metabolism. Science 268, 585-586 (1995).
58. Gunton, J. E., Stiel, J., Clifton-Bligh, P., Wilmshurst, E. & McElduff, A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur. J. Endocrinol. 142, 587 (2000).
59. Gao, Y. et al. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int. Immunopharmacol. 7, 55-60 (2007). (Pubitemid 44856387)
60. Ye, H., Gao, Y., Guo, X. H. & Zhao, M. H. Titre and affinity of propylthiouracil-induced anti-myeloperoxidase antibodies are closely associated with the development of clinical vasculitis. Clin. Exp. Immunol. 142, 116-119 (2005). (Pubitemid 41361013)
61. Gao, Y. et al. Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis. Clin. Endocrinol. (Oxf.) 66, 543-547 (2007). (Pubitemid 46434937)
62. Fujieda, M. et al. Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves disease treated with propylthiouracil. Clin. Nephrol. 63, 437-445 (2005). (Pubitemid 40872622)
63. Yu, F., Zhao, M. H., Zhang, Y. K., Zhang, Y. & Wang, H. Y. Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)- induced ANCA positive vasculitis are associated with disease activity. Clin. Exp. Immunol. 139, 569-574 (2005). (Pubitemid 40333269)
64. Herlin, T., Birkebaek, N. H., Wolthers, O. D., Heegaard, N. H. & Wiik, A. Anti-neutrophil cytoplasmic autoantibody (ANCA) profiles in propylthiouracil-induced lupus-like manifestations in monozygotic triplets with hyperthyroidism. Scand. J. Rheumatol. 31, 46-49 (2002). (Pubitemid 34169451)
65. Yu, F. et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am. J. Kidney Dis. 49, 607-614 (2007). (Pubitemid 46654487)
66. Chen, Y. X. et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: A comparative study. J. Rheumatol. 39, 558-563 (2012).
67. Chen, Y. X. et al. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: Retrospective study of 19 cases. J. Rheumatol. 34, 2451-2456 (2007).
68. Schur, P. H. IgG subclasses-a review. Ann. Allergy 58, 89-96 (1987).
69. Gao, Y., Ye, H., Yu, F., Guo, X. H. & Zhao, M. H. Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin. Immunol. 117, 87-93 (2005). (Pubitemid 41725474)
70. Aalberse, R. C., Van Der Gaag, R. & Van Leeuwen, J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J. Immunol. 130, 722-726 (1983). (Pubitemid 13186294)
71. Ye, H., Zhao, M. H., Gao, Y., Guo, X. H. & Wang, H. Y. Antimyeloperoxidase antibodies in sera from patients with propylthiouracil- induced vasculitis might recognize restricted epitopes on myeloperoxidase molecule. Clin. Exp. Immunol. 138, 179-182 (2004). (Pubitemid 39279982)
72. Yung, R. L. & Richardson, B. C. Drug-induced lupus. Rheum. Dis. Clin. North Am. 20, 61-85 (1994).
73. Bilge, N. S., Kasifoglu, T. & Korkmaz, C. PTU-induced ANCA-positive vasculitis: An innocent or a life-threatening adverse effect? Rheumatol. Int. http://dx.doi.org/10.1007/s00296 011 2280-5.
74. Flendrie, M. et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res. Ther. 7, R666-R676 (2005).
75. Doyle, M. K. & Cuellar, M. L. Drug-induced vasculitis. Expert Opin. Drug Saf. 2, 401-409 (2003).
76. Vasoo, S. Drug-induced lupus: An update. Lupus 15, 757-761 (2006).
77. Sheen, Y. S., Chu, C. Y. & Yu, H. S. Antineutrophil cytoplasmic antibody-positive cutaneous leukocytoclastic vasculitis associated with propylthiouracil therapy. Arch. Dermatol. 142, 879-880 (2006).
78. Merkel, P. A. Drug-induced vasculitis. Rheum. Dis. Clin. North Am. 27, 849-862 (2001). (Pubitemid 33054997)
79. Maguchi, S., Fukuda, S., Chida, E. & Terayama, Y. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated sensorineural hearing loss. Auris Nasus Larynx 28, S103-S106 (2001).
80. Sano, M., Kitahara, N. & Kunikata, R. Progressive bilateral sensorineural hearing loss induced by an antithyroid drug. ORL J. Otorhinolaryngol. Relat. Spec. 66, 281-285 (2004). (Pubitemid 39664132)
81. Colakovski, H. & Lorber, D. L. Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis. Endocr. Pract. 7, 37-39 (2001). (Pubitemid 32834244)
82. Darben, T., Savige, J., Prentice, R., Paspaliaris, B. & Chick, J. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas. J. Dermatol. 40, 144-146 (1999). (Pubitemid 29374364)
83. Hong, S. B. & Lee, M. H. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology 208, 339-341 (2004).
84. Vanek, C. & Samuels, M. H. Central nervous system vasculitis caused by propylthiouracil therapy: A case report and literature review. Thyroid 15, 80-84 (2005). (Pubitemid 40223505)
85. Abe, T. et al. Cerebral pachyleptomeningitis associated with MPO-ANCA induced by PTU therapy. Intern. Med. 46, 247-250 (2007). (Pubitemid 46403668)
86. Ishii, R. et al. A long-term follow-up of serum myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil. Endocr. J. 57, 73-79 (2010).
87. Morais, P. et al. Antineutrophil cytoplasmic antibody (ANCA)-positive cutaneous leukocytoclastic vasculitis induced by propylthiouracil confirmed by positive patch test: A case report and review of the literature. Cutan. Ocul. Toxicol. 30, 147-153 (2011).
88. Irani, F., Elkambergy, H., Naraharisetty, K. & Jamal, R. Propylthiouracil-induced leucocytoclastic vasculitis with pulmonary hemorrhage treated with plasmapheresis. Am. J. Med. Sci. 337, 470-472 (2009).
89. Dhillon, S. S. et al. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 116, 1485-1488 (1999). (Pubitemid 29536015)
90. Jennette, J. C. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37, 187-192 (1994). (Pubitemid 24065492)
91. Radic, M., Martinovic Kaliterna, D. & Radic, J. Drug-induced vasculitis: A clinical and pathological review. Neth. J. Med. 70, 12-17 (2012).
92. Cuellar, M. L. Drug-induced vasculitis. Curr. Rheumatol. Rep. 4, 55-59 (2002).
93. Gao, Y. et al. Long-term outcomes of patients with propylthiouracil- induced anti-neutrophil cytoplasmic auto antibody associated vasculitis. Rheumatology (Oxford) 47, 1515-1520 (2008).